Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.80 | N/A | +1.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.80 | N/A | +1.42% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism about future projects. They emphasized the importance of innovation while recognizing competitive pressures.
Management highlighted ongoing efforts in research and development.
They expressed confidence in their pipeline but acknowledged market challenges.
Pfizer's earnings report showed a slight beat on EPS, which indicates some positive performance. However, the stock fell by 3.81%, likely due to the lack of revenue details and forward guidance. Investors may be concerned about the company's future prospects given the competitive landscape and absence of specific targets.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHILLIPS 66
Jul 26, 2019